Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bright Minds Biosciences (DRUG) Common Equity: 2020-2021

  • Bright Minds Biosciences' Common Equity was N/A to $22.2 million in Q2 2021 from the same period last year, while for Jun 2021 it was $22.2 million, marking a year-over-year change of. This contributed to the annual value of $654,859 for FY2020, which is N/A change from last year.
  • According to the latest figures from Q2 2021, Bright Minds Biosciences' Common Equity is $22.2 million, which was up 3,263.19% from $660,535 recorded in Q3 2020.
  • Bright Minds Biosciences' Common Equity's 5-year high stood at $22.2 million during Q2 2021, with a 5-year trough of $660,535 in Q3 2020.
  • In the last 2 years, Bright Minds Biosciences' Common Equity had a median value of $11.4 million in 2020 and averaged $11.4 million.